SMC Biotechnology Announces Publication of Bone Repair Data

Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!

REDWOOD CITY, Calif., July 10, 2013 (GLOBE NEWSWIRE) -- SMC Biotechnology, a regenerative medicine company focused on developing carbohydrate compounds that enhance tissue regeneration, announced today that data published in the online journal, Biomaterials, suggests that its proprietary sugar compound, SMC-103 greatly enhances bone repair. Researchers found that affinity-selected heparan sulfate (HS) improved bone repair by increasing the bioavailability, bioactivity and half-life of the pro-healing compound, bone morphogenetic protein-2 (BMP-2). SMC-103 is a glycosaminoglycan, or GAG, a naturally occurring substance composed of chains of paired sugar units. SMC Biotechnology is currently developing SMC-103 as a bone-healing device that can be delivered to the exact site of injury or damage to augment the body's natural healing process.

Help employers find you! Check out all the jobs and post your resume.
MORE ON THIS TOPIC